Contraindications to Lubiprostone for Constipation
Lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. 1
This is the only absolute contraindication explicitly stated in the FDA drug label and represents a critical safety concern that must be ruled out before initiating therapy.
Clinical Reasoning
The contraindication stems from lubiprostone's mechanism of action as a chloride channel-2 activator that increases intestinal fluid secretion 2. In the presence of mechanical obstruction, this increased fluid secretion could:
- Worsen luminal distension proximal to the obstruction
- Potentially lead to perforation or other serious complications
- Exacerbate symptoms rather than provide relief
Pre-Treatment Evaluation
Before prescribing lubiprostone, perform a thorough evaluation in any patient with symptoms suggestive of mechanical gastrointestinal obstruction to confirm its absence. 1 Red flag symptoms requiring investigation include:
- Severe, progressive abdominal pain
- Persistent vomiting
- Abdominal distension with high-pitched bowel sounds or absence of bowel sounds
- History of abdominal surgery with adhesions
- Known structural abnormalities (strictures, tumors)
Important Dose Adjustments (Not Contraindications)
While not absolute contraindications, patients with moderate to severe hepatic impairment require dose reduction 2, 1:
- Moderate hepatic impairment (Child-Pugh Class B): Reduce to 16 mcg twice daily for CIC/OIC; no adjustment needed for IBS-C
- Severe hepatic impairment (Child-Pugh Class C): Reduce to 8 mcg twice daily for CIC/OIC; 8 mcg once daily for IBS-C
Common Pitfalls to Avoid
- Do not confuse severe diarrhea with a contraindication: While the label advises avoiding lubiprostone in patients with severe diarrhea 1, this is a precaution rather than an absolute contraindication
- Pregnancy considerations: Lubiprostone is not contraindicated in pregnancy, though it should be used with appropriate risk-benefit assessment
- Renal impairment: No contraindication or dose adjustment is required for renal dysfunction, as systemic absorption is negligible 2